Influence of prostaglandin A2 and 2-methoxyestradiol on telomerase activity in cancer cell lines and a non-tumorigenic epithelial breast cell line

Biomedical Research

Volumn 24, Issue 3, 2003, Pages 125-131

  Joubert, Annie ^a   Maritz, Christine ^a   Appelgryn, Rencia ^a   Du Toit, Petrus ^a   Lottering, Mona Liza ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; PROSTAGLANDIN A2; TELOMERASE;

ARTICLE; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; HELA CELL; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 27244438096     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.24.125     Document Type: Article

References (36)

1. Aldous W. K., Marean A. J., DeHart M. J., Matej L.A., and Moore K.H. (1999) Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer 85, 1523-1529.
2. Bregman M. D., Funk C., and Fukushima M. (1986) Inhibition of human melanoma growth by prostaglandin A, D, and J analogues. Cancer Res. 46, 2740-2744.
3. Bryan T. M., Englezou A., Gupta J., Bacchetti S., and Reddel R. R. (1995) Telomere elongation in immortal human cells without detectable telomerase activity EMBO J. 14, 4240-4248.
4. Chin L., Artandi S. E., Shen Q., Tam A., Lee S. L., Gottlieb G. J., Greider C. W. and DePinho R. A. (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527-538.
5. Cushman M., He H-M., Katzenellenbogen J. A., Lin C. M., and Hamel E. (1995) J. Med. Chem. 38, 2323-2041.
6. De Kock M., Seegers J. C., and Els H. J. (1992) Effects of gamma-linolenic acid on mitosis and nuclear morphology in osteogenic sarcoma cells. S. Afr. Med. J. 81, 467-472.
7. Fotsis T., Zhang Y., Pepper M. S., Adlerkreutz H., Montesano R., Nawroth P. P., and Schweigerer L. (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368, 237-239.
8. Franzese O., Comandini A., Cannavo E., Pepponi R., Falcinelli S., Graziani G., and Bonmassar E. (1998) Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Melanoma Res. 8, 323-328.
9. 1 arrest and preclinical results. Ann. N. Y. Acad. Sci. 744, 161-165.
10. Harley C. B., Kim N. W., Prowse K. R., Weinrich S. L., Hirsch K. S., and West M. D. (1994) Telomerase, cell immortality and cancer. Cold Spring Harb. Symp. Quant. Biol. 59, 307-315.
11. http://entremed.com/pipeline/panzem/clinical.cfm. Internet access: 3 April 2003.
12. Isaacs J. S., Barrett J. C., and Weissman B. E. (1999) Interference of proteins involved in the cytoplasmic sequestration of p53 with human papillomavirus E6-mediated degradation. Mol. Carcinog. 24, 70-77.
13. Joseffson E., and Tarkowski A. (1997) Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum. 40, 154-163.
14. 2 on cell growth, cell cycle status and apoptosis induction in HeLa and MCF-7 cells. Cancer Lett. 191, 203-209.
15. Joubert A. M., Panzer A., Joubert F., Lottering M. -L.,. Bianchi P. C., and Seegers J. C. (1999) Comparative study of the effects of polyunsaturated fatty acids and their metabolites on cell growth and tyrosine kinase activity in oesophageal carcinoma cells. Prostaglandins Leukot. Essent. Fatty Acids 61, 171-182.
16. Karlseder J., Broccoli D., Dai Y., Hardy S., and de Lange T. (1999) p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283, 1321-1325.
17. Kikuchi Y., Kita T., Hirata J., Kuki E., Nagata I., and Fukushima M. (1992) Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins. Int. J. Immunopharmacol. 14, 105-110.
18. LaVallee T. M., Zhan X. H., Herbstritt C. J., Kough E. C., Green S. J., and Pribluda V. S. (2002) 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 62, 3691-36977.
19. Lavelle F., Riou J., Laoui A., and Mailliet P. (2000) Telomerase: a therapeutic target for die third millennium? Crit. Rev. Oncol. Hematol. 34, 111-126.
20. Lippert C., Seeger H., and Mueck A. O. (2003) The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci. 10, 877-883.
21. Lottering M., Haag M., and Seegers J. C. (1992) Effects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res. 52, 5926-5932.
22. Milyavsky M., Mimran A., Senderovich S., Zurer I., Erez N., Shats I., Goldfinger N., Cohen I., and Rotter V. (2001) Activation of p53 protein by telomeric (TTAGGG)n repeats. Nucleic Acids Res. 29, 5207-5215.
23. Narumiya S., and Fukushima M. (1986) Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J. Pharmacol. Exp. Ther. 239, 500-505.
24. 2 in nuclei. J. Pharmacol. Exp. Ther. 242, 306-311.
25. 2-induced growth inhibition. Biochem. Biophys. Res. Commun. 139, 808-815.
26. 1-enriched HeLa S3 cells. J. Pharmacol. Exp. Ther. 245, 294-298.
27. Rhyu M. S. (1995) Telomeres, telomerase, and immortality. J. Natl. Cancer Inst. 87, 884-94.
28. Sasaki H. (1994) Fukushima M. Prostaglandins in the treatment of cancer. Anticancer Drugs 5, 131-138.
29. Seegers J. C., Aveling M. L., Van Aswegen C. H., Cross M., Koch F., and Joubert W. S. (1989) The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. Steroid Biochem. 32, 797-809.
30. Seegers J. C., Lottering M. -L., Habbersett R C., Shouy Y., and Lenhnert B. E. (1997) The mammalian metabolite, 2-methoxyestradiol, affects p-53 levels and apoptosis induction in transformed cells but not in normal cells. J. Steroid. Biochem. Mol. Biol. 62, 253-254.
31. Snijders P. J., van Duin M., Walboomers J. M., Steenbergen R. D., Risse E. K., Helmerhorst T. J., Verheijen R. H., and Meijer C. J. (1998) Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 58, 3812-3818.
32. Thomas M., and Banks L. (1998) Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17, 2943-2954.
33. White K. L., Wright E. W., and Shay J. W. (2001) Telomerase inhibitors. Trends Biotechnol. 19, 114-120.
34. Wisman G. B., Hollema H., de Jong S., ter Schegget J., Tjong-A-Hung S. P., Ruiters M. H., and van der Zee A. G. (1998) Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smears. J. Clin. Oncol. 16, 2238-2245.
35. Yue T-L, Wang X, Louden CS, Gupta S, Pillarisetti J-L, Hart TK, et al. (1997) 2- Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: a possible role in stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharm. 51, 951-11.
36. Zimmermann H., Degenkolbe R., Bernard H. U., and O'Connor M. J. (1999) The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73, 6209-6219.